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Abstract 
Objective 
Only a few studies have investigated the changes in carotid intima–media thickness (IMT) over 
time, and uncertainties remain on the underlying mechanisms linking depression and subclinical 
atherosclerosis. We carried out a prospective cohort study to evaluate whether depression is 
associated with changes in carotid IMT in subjects with cardiac risk factors but free from coronary 
heart disease (CHD), and to what extent the atherogenicity of depression can be explained by 
inflammatory markers and autonomic nervous system dysfunction. 
Methods 
During baseline and follow-up visits: all participants were asked to provide blood samples and 
compile a structured questionnaire; trained physicians assessed depression symptoms using Beck 
Depression Inventory (BDI); altered cardiac autonomic tone was measured using time-domain 
components of heart rate variability in 24 h Holter recordings; measurements of carotid IMT were 
carried out using B-mode ultrasound image acquisition. Logistic and linear regression analyses 
were used to adjust for potential confounders and explore potential mediators. 
Results 
A total of 381 subjects completed the 5-year follow-up. The mean carotid IMT significantly 
increased in all subjects but the amount of increase was significantly larger among subjects with 
depression symptoms: mean IMT increased by 0.16 ± 0.14 mm; 0.31 ± 0.28 mm and 0.61 ± 0.54 
mm among the subjects with no, mild and moderate/severe depression, respectively (all p < 0.01). 
The association between moderate/severe depression and IMT increase remained highly significant 
even after controlling for all the variables considered, however when both IL-6 and CRP were 
included in multivariate models the regression coefficient decreased by 42.3%. Some of the 
inflammation markers and autonomic nervous system dysfunction were also independently 
correlated with carotid IMT increase. 
Conclusion 
Depression symptoms are independently associated with an accelerated progression of carotid IMT 
in subjects with CHD risk factors, and inflammation may substantially modulate the association 
between depression and carotid IMT progression. 
Keywords: 
Depression, Coronary heart disease, Intima media-thickness, Autonomic nervous system, 
Inflammation 
  
Introduction 
Depression symptoms are independently associated with cardiovascular events in healthy subjects 
and in patients with heart disease [[1], [2], [3]]. In the last decade, depression symptoms have also 
been related to the progression of subclinical atherosclerosis [[4], [5], [6], [7], [8], [9]]. However, 
only a few studies with short follow-up have investigated the changes in carotid intima–media 
thickness (IMT) over time [[4], [5], [6], [7]], and uncertainties remain on the underlying 
mechanisms linking depression and subclinical atherosclerosis. 
Among the potential explanations that have been advocated for the observed association there are 
lifestyle [10], modifications in platelet function [11] and endothelial dysfunction [12]. In addition, 
depression symptoms have been associated with autonomic nervous system dysregulation, due to 
sympathetic activation and/or vagal withdrawal [13]. Heart rate variability [HRV] imbalance, an 
index of the autonomic nervous system, might increase the risk of mortality in depressed patients 
through myocardial ischemia and ventricular arrhythmia, and could stimulate inflammation [[14], 
[15]]. Furthermore, depression symptoms have been related to an inflammation response in the 
general population and in patients with heart disease. Indeed, the relationship between autonomic 
nervous system dysfunction and inflammation is well documented and is one of the earliest steps in 
the development of atherosclerosis. Thus, it is plausible that depression exerts an effect on the 
progression of atherosclerosis through autonomic nervous system imbalance and higher levels of 
inflammation [16]. 
To our knowledge, only the Pittsburgh Healthy Heart Project study has examined the correlation 
between subclinical atherosclerosis, depression symptoms and cardiac risk factors [7]. The authors 
found that depressive symptoms were associated with the progression of atherosclerosis as 
measured by a change in carotid intima–media thickness. Such finding, however, was not accounted 
for some important potential confounders including baseline IMT, demographic factors, 
cardiovascular risk factors, medication use, and medical conditions. We carried out a prospective 
cohort study to evaluate whether depression is associated with changes in carotid IMT after 5 years 
of follow-up in subjects with cardiac risk factors but free from coronary heart disease (CHD), and to 
what extent the atherogenicity of depression can be explained by inflammatory markers and 
autonomic nervous system dysfunction. 
2. Methods 
2.1. Study population and design 
All CHD-free individuals presenting to our department (from primary care referral) between 
September 2003 and November 2005 were asked to participate. The initial eligibility criteria 
included the presence of at least two among the following CHD risk factors: age ≥60 years, male 
gender, current smoking (≥1 cigarette per day), hypertension (systolic blood pressure > 140 mmHg 
or diastolic blood pressure > 90 mmHg or current treatment for hypertension), dislipidemia (serum 
cholesterol > 240 mg/dL, or triglycerides > 150 mg/dL, or current treatment for dislipidemia) and 
family history of CHD (if at least one of the parents or siblings aged ≤55 years had CHD). 
Exclusion criteria were the presence of a neoplasm, kidney or liver failure, systemic inflammatory 
disease and/or current antidepressant treatment, left bundle block, paced rhythm, Wolff–Parkinson–
White syndrome or pathophysiological conditions which could alter the analysis of heart rate 
variability: diabetes mellitus, peripheral neuropathy, atrial fibrillation and an ejection fraction <45% 
[17]. We also excluded subjects with an IMT > 1.5 mm at baseline because such values are 
indicative of plaque according to the joint European Society of Hypertension (ESH)/European 
Society of Cardiology (ESC) guidelines [18]. 
The study had a prospective cohort design, and all participants were requested to undergo follow-up 
examinations 5 years after baseline evaluation (between September 2008 and November 2010). All 
participants provided written informed consent and the study protocol was approved by the local 
ethical committee. 
2.2. Interview and measurements 
During baseline and follow-up visits, all participants were asked to compile a structured 
questionnaire including items on socio-demographic characteristics, CHD risk factors, medical 
history, and current medication use. In addition to the questionnaire, information was collected by 
means of blood sampling. Total cholesterol and triglycerides were measured using commercial kits 
in an automatic analyzer (Boehringer); HDL cholesterol using enzymatic methods (Boehringer), 
and LDL cholesterol was computed according to the Friedewald formula. We also recorded C-
reactive protein (CRP) (Latex/BN II, Dade Behring) and Interleukin-6 (IL-6, Quantikine human IL-
6). 
At both baseline and follow-up examination, we also separately assessed depression symptoms, 
IMT and indices of the autonomic nervous system. 
2.3. Depression 
Depression was evaluated using the Beck Depression Inventory (BDI), a 21-item self-reported 
measurement of depressive symptomatology. The BDI score can be divided into three categories 
ranging from no depression to severe depression (score ≤10-no depression; score >10–18-mild 
depression, score ≥19-moderate/severe depression) [19]. 
2.4. Assessment of heart rate variability 
To measure altered cardiac autonomic tone, we used the time-domain components of Heart Rate 
Variability in 24-h Holter recordings as previously described [[13], [16]]. The following parameters 
were considered in the analysis: standard deviation (SD) for the time between normal-to-normal 
complexes in the entire 24 h electrocardiographic recording (SDNN), SD of the average normal-to-
normal intervals for each 5-min period (SDANN), root-mean square of the differences in successive 
R wave to R wave (RR) intervals (RMSSD), and the percentage of adjacent RR intervals >50 ms 
apart (pNN50). Under these conditions, SDNN and SDANN were indices of both parasympathetic 
and sympathetic tone as mediated by baroreflex activity; RMSSD and pNN50 were measurements 
of the modulation of parasympathetic tone [16]. 
2.5. Carotid artery studies 
Ultrasound exams were carried out using an Esaote Caris Plus machine (Rome, Italy) with 7.5–10.0 
MHz linear array transducers. The measurement of the carotid IMT was carried out using B-mode 
ultrasound image acquisition. The sonographer was also the reader of the exam for all 
measurements, and was blinded to patients' identity. The left and right carotid artery were scanned 
by ultrasound technicians following a standardized protocol. In brief, image acquisition included the 
evaluation of the right and left common carotid arteries, 1 cm proximal to the carotid bulb. The far 
left and right walls of the carotid artery segments were imaged in a standardized magnification (2 × 
2 cm). The sonographer used different scanning angles to identify the maximum thickness of the 
IMT, 1 cm proximal to the carotid bulb. Carotid IMT measurements were performed offline with 
IMAGE-Pro version 5.1 (Microsoft) image-analysis software. Recorded image sequences (on S-
VHS tapes) were reviewed frame by frame to select the best-quality images for measurement. IMT 
for the common carotid artery was defined as the mean of the maximum wall thicknesses for the 
near and far walls on the right and left common carotid segments: (maximum near left wall + 
maximum far left wall + maximum near right wall + maximum far right wall)/4. For each segment, 
IMT was defined as the average of 3 measurements [[17], [20]]. Inter-observer comparisons showed 
a mean measurement variation equal to 0.04 mm (SD = 0.07 mm; range −0.13 to 0.13 mm). 
2.6. Statistical analyses 
Standard univariate analyses were initially used to compare the baseline characteristics of subjects 
with no (BDI < 10), mild (9 < BDI < 19) or moderate/severe depression symptoms (BDI ≥ 19); one-
way ANOVA with a Sidak correction was used for continuous variables and the chi-squared test for 
categorical variables. For all inflammatory markers, heart rate variability and subclinical 
atherosclerosis, the percentage of change between the end and the start of the follow-up was also 
computed and compared across depression groups using ANOVA with a Sidak correction. 
As regards the main outcome of the study, namely the mean IMT increase from baseline to the end 
of the five-year follow-up (±2 months), separate analyses were initially carried out for left and right 
IMTs. However, given the collinearity between the left and the right IMTs, both at baseline and at 
the end of the follow-up (Spearman rho = 0.93 and 0.96, respectively), we based all analyses on the 
mean IMT value between the right and the left side to avoid redundancy. 
The independent predictors of IMT increase were investigated in separate steps using multiple 
regression: 1) depression group as the only explanatory variable; 2) adding demographic and CHD 
risk factors (age, gender, body mass index, current smoking, familial history of CHD, systolic blood 
pressure, total cholesterol, HDL cholesterol, triglycerides and global CHD risk at ten years 
according to the SCORE [21] system); 3) adding the use of selected drugs (beta-blockers, ACE-
antagonists, calcium-antagonists, diuretics, sartans, statins, selective serotonin reuptake inhibitors 
(SSRIs), aspirin); 4) adding time-domain measurements of heart-rate variability (heart rate, SDNN, 
SDANN, RMSSD, pNN50) and 5) adding Interleukin-6 and C-Reactive Protein. At each step, the 
association between the depression group and the IMT was re-examined. The depression status – 
BDI score – was treated either as a continuous or categorical variable: given R2 values, likelihood 
ratio test results, clinical relevance and easiness of interpretation, finally substantially different 
coefficients, depression was considered categorical into the final model, including three levels of 
symptom severity as dummy variables: no, mild, and moderate/severe depression [19]. 
Some of the covariates were skewed and transformed (logarithm: C-Reactive Protein and SDNN; 
square root: SDANN and RMSSD; cubic: Interleukin-6). To facilitate the interpretation of the 
complex autonomic indices, however, their values were transformed back to the original units 
yielding geometric means. In addition to regression coefficients, standardized coefficients were also 
computed to investigate the most important domains in predicting IMT increase. 
Once the final fully-adjusted model was fit, its validity was assessed as follows. The assumption of 
constant error variance was checked graphically, plotting Pearson residuals versus fitted values, and 
formally, using Cook and Weisberg's test for heteroskedasticity. High leverage observations were 
identified by computing Pearson, standardized and studentized residuals, Cook's D influence, 
Welsch distance and DFBETA. We found 32–50 high leverage observations and repeated the 
analysis excluding those observations with no substantial changes. However, given that the number 
of outliers was larger than 5% of the sample, all models were conservatively based upon robust 
standard errors. Finally, since the dependent variable was slightly skewed, we repeated all the 
analyses using its square root as the dependent variable, with no appreciable changes; IMT increase 
was thus kept in the models in its original form to facilitate interpretation. 
As a secondary additional analysis, we investigated whether depressed subjects had a higher 
likelihood of developing carotid wall thickening (defined as a IMT > 0.9 mm) during the follow-up 
[[18], [20]]. We excluded the subjects who already had IMT > 0.9 mm at baseline, and compared 
the proportion of subjects developing carotid wall thickening according to the depression group 
using logistic regression. Covariates were selected a priori according to their clinical relevance, and 
were limited to 16 to reduce the risk of overfitting. The goodness of fit of the logistic model was 
assessed using the Hosmer–Lemeshow test, and the predictive power was evaluated computing the 
area under the Receiving Operator Curve. In the logistic model, depression was treated ordinally 
because mild and moderate/severe depression adjusted odds ratios (ORs) were substantially similar. 
Statistical significance was defined as a two-sided p-value <0.05 for all analyses, which were 
carried out using STATA software, version 10.1 (Stata Corp., College Station, Texas, USA, 2007). 
3. Results 
3.1. Baseline characteristics 
A total of 590 subjects were asked to participate; 391 of them fulfilled the selection criteria and 
composed the final sample. The present analysis examined the data from the 381 subjects who had 
complete baseline and follow-up data on ultrasound examinations, depression, heart rate variability 
and inflammation markers. The reasons for exclusion were death (n = 6), unwillingness to 
participate (n = 2) and unknown (n = 2). 
At baseline, a total of 87 (22.8%) subjects showed depressive symptomatology (n = 47 with mild 
and n = 40 with moderate/severe depression). At univariate analysis (Table 1, Table 2, Table 3), as 
compared with subjects without depression, individuals with depression symptoms were more 
likely to be obese, have higher levels of inflammatory markers, triglycerides, total and LDL 
cholesterol, and to experience some degree of autonomic nervous system dysfunction (SDNN and 
SDANN). 
3.2. Follow-up characteristics 
 
During the follow-up, only seven subjects improved, but none progressed from depression (either 
mild or moderate/severe) to normality. Of the seven who improved, four were assuming SSRIs (out 
of 24; 16.7%), and three were not assuming SSRIs (out of 63; 4.8%). 
At the end of the 5-year follow-up, the BMI of subjects with depression remained substantially 
stable (from 26.5 ± 4.0 to 27.2 ± 3.6 kg/m2), LDL cholesterol decreased by 16%, HDL cholesterol 
by 21%, systolic blood pressure by 8%, and diastolic blood pressure by 19% (all p < 0.01). 
Although there were no subjects with diabetes at baseline, 10% (n = 9) of them had diabetes five 
years later. The use of drugs for hypercholesterolemia increased from 27 to 31%, and the number of 
subjects on antihypertensive treatment rose from 57 to 61%. At baseline, the patients with 
depression were not taking SSRIs; however, at the end of the follow-up, 24 patients with depression 
symptoms were being treated with SSRIs. 
By the end of follow-up, baseline CRP and IL-6 increased among moderate/severe depression 
patients but did not change or decreased into the no/mild depression groups. However, heart rate 
tended to decrease in moderate/severe depression patients (Table 2). Compared with non-depressed 
subjects, those with depression showed the lowest SDNN and SDANN values at the end of follow-
up. 
3.3. IMT progression 
The mean carotid IMT significantly increased in all subjects during the 5-year follow-up (all p < 
0.001 – Table 3). However, the amount of increase significantly differed by depression status at 
baseline: the average IMT increases were 0.16 ± 0.14 mm; 0.31 ± 0.28 mm and 0.61 ± 0.54 mm 
among the subjects with no depression, mild depression and moderate/severe depression, 
respectively (all p < 0.01). Such values, expressed as the percentage of IMT increase, corresponded 
to 21.8%, 39.8% and 59.9%, respectively. 
At multivariate analysis, moderate/severe depression showed a significant association with an IMT 
increase in all models, even after controlling for all the variables considered (Table 4). Also mild 
depression showed a significant positive coefficient of IMT increase during the follow-up, however 
the significance was lost (p = 0.068) when the model was adjusted to also include IL-6 and CRP. 
Importantly, the latter variables were the only covariates which relevantly influenced the 
association between depression and IMT increase: when both IL-6 and CRP were included in the 
multivariate model, the regression coefficients decreased by 51.3% and 42.3% for mild and 
moderate/severe depression, respectively (Table 4). With regard to mild depression, in any case, the 
lack of significance might also be due to a sample which was relatively scarce for a multivariate 
model including more than 20 variables. 
Unsurprisingly, the subjects with depression symptoms also showed a significantly higher 
likelihood of developing carotid wall thickening (IMT > 0.9 mm) during the follow-up (adjusted 
OR: 1.96 – p = 0.032 – Table 5). 
Other than depression, the only significant independent predictors of an increase in IMT were 
increasing CRP, aspirin use, familial history of CHD, and decreasing SDNN (all p < 0.05; Table 4). 
 
The statistical power to detect a difference in mean IMT change (or in the proportion of IMT > 0.9 
mm during follow-up) between no depression and mild depression groups was higher than 90% in 
both linear and logistic regression models. 
 
4. Discussion 
To date, only a few studies have examined the relationship between depression symptoms and 
change in carotid IMT over time, with contrasting results [[4], [5], [6], [7]]. To our knowledge, 
however, this is the first study in which the analyses were adjusted for the main potential 
confounders and underlying mechanisms (CHD risk factors, inflammation and autonomic nervous 
system dysfunction). In our sample of subjects with CHD risk factors but free from CHD disease, 
we found that, as compared to non-depressed subjects, the individuals with moderate/severe 
depression symptoms showed a significantly larger IMT increase during the 5-year follow-up. This 
finding remained highly significant after adjusting for several potential confounders or mediators 
including age, gender, main CHD risk factors, inflammatory markers and indices of autonomic 
nervous dysfunction. Importantly, the magnitude of the association between depression and 
subclinical atherosclerosis substantially decreased (halved) when some of the inflammation markers 
– CRP and IL-6 – were also included in the multivariate analyses. 
Our findings confirm and expand those by Stewart et al. on a sample of 464 adults [7], but are in 
contrast with the conclusions by Rice et al. [4]. These different results, however, can be explained 
by the differences in the definition of depression, participants, and length of follow-up. In fact, Rice 
et al. evaluated depressive symptoms according to the Center for Epidemiological Studies-
Depression, in the general population, who was followed for an average of 3.9 ± 2.28 years [4]. 
Finally, their conclusions might also have been influenced by a potential lack of statistical power, 
due to the relatively small sample size (n = 68). 
As regards the autonomic nervous system and inflammation markers, in addition to the above-
mentioned role in mediating (or not) the association between depression and subclinical 
atherosclerosis, we found an independent association between IMT increase and CRP and SDNN, 
an index of autonomic nervous system dysfunction. Our results are in line with previous findings 
suggesting that an imbalance of the autonomic nervous system is related to the extent and 
progression of carotid atherosclerosis in type 2 diabetic patients [22] and in healthy subjects [23]. 
Indeed, it has been suggested that autonomic nervous system dysfunction, a reflection of both 
sympathetic hyperactivity and/or parasympathetic withdrawal, favors several factors promoting 
atherogenesis: insulin resistance, platelet aggregation, lipoprotein metabolism, gene expression and 
the protein production of several inflammatory cytokines [16]. In fact, recent studies have suggested 
that a low grade of inflammation was modulated by autonomic nervous system dysfunction [[16], 
[24]]. This relationship was found in both depressed [19] and non-depressed patients [24]. 
Conversely, pro-inflammation cytokines, such as IL-6 and tumor necrosis factors, potentially 
influence nervous autonomic activity. 
 
Several issues remain to be elucidated on the relationship between depression and inflammation 
[25]. Our findings suggest that depression symptoms and inflammation have some degree of 
interaction; however they may separately and independently predict the progression of carotid IMT. 
This finding is again in line with previous studies reporting an independent association of 
inflammation and depression [[26], [27]]. Vaccarino et al. observed that the cardiovascular 
mortality risk associated with depression is reduced by 13% when adjusting for CRP, and by 4% 
when adjusting for IL-6 [26]. In the study carried out by Whooley et al., depressive symptoms 
remained associated with a 31% greater rate of cardiovascular events after being adjusted for 
comorbid conditions and cardiac disease severity. However, additional adjustment for C-reactive 
protein nullified this association. Importantly, these studies have suggested that inflammation 
markers explain only a small portion of the CHD risk associated with depression symptoms [27]. 
Our findings suggest that aspirin may attenuate the progression of intima–media thickness of the 
carotid artery wall of subjects with coronary risk factors but free from disease. However, our study 
was not focused on such hypothesis and had an observational design. Therefore, specifically 
targeted randomized controlled trials would be needed to confirm the above association. 
4.1. Study limitations 
Strengths of the study are the relatively large sample and the prospective design, a well-
characterized cohort and the collection of several variables of different domains that may be related 
to the effects of depression and to the progression of atherosclerosis. However, this study also had 
some limitations which must be considered in interpreting the results. First, the follow-up lasted 
five years, which is a reasonable time to detect variations in the risk of subclinical atherosclerosis 
but does not allow definitive conclusions. Second, the carotid IMT reflected the cumulative effects 
of risk factors acting over a period of many years, whereas we measured risk factors only at 
baseline and at the end of the follow-up. It is also true that it would be extremely difficult to carry 
out a life-long trial to study the progression of atherosclerosis in depressed patients. Third, a 
statistical association between a risk factor and atherosclerotic changes does not prove that the risk 
factor directly promotes atherogenesis. However, we adjusted for a large number of factors in the 
analysis, including most of the known CHD risk factors (and potential confounders). Fourth, 
excluding the subjects with IMT values indicative of plaques (>1.5 mm), we may have selected a 
subgroup of subjects particularly protected against the disease. However, given that we 
hypothesized that autonomic dysregulation and inflammation play a role in depression, these 
mechanisms may come into play not only in the amplification and complication of advanced forms 
of disease, but also in the initiation and progression of the early disease in bridging depression and 
vascular atherosclerosis. Consequently, it was preferred to include only asymptomatic patients, 
without clinically overt forms of CHD and carotid plaque, that may have provided the highest signal 
and reinforced our hypothesis. 
5. Conclusions 
In subjects with coronary risk factors but free from CHD, depression symptoms were independently 
associated with carotid IMT progression during the follow-up. Some of the inflammation markers 
and autonomic nervous system dysfunction were also independently correlated with carotid IMT 
increase. Our findings suggest that inflammation may substantially modulate the association 
between depression and carotid IMT progression. Our results should be confirmed by additional 
research, which is strongly needed to enhance our comprehension of the multifactorial 
pathophysiological pathways linking depression to atherosclerosis. 
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Table 1General characteristics of the sample at baseline. 
 
 
No depression 
(n = 294) 
Mild depression 
(n = 47) 
Moderate–severe 
depression (n = 40) 
p < 0.05 
Continuous variables      (mean ± SD) 
Age, y 57.7 ± 8.8 56.2 ± 8.6 56.8 ± 9.3 
 
BMI, kg/m
2
 (median, 
IQR) 
26.2 ± 3.9 25.5 ± 6.6 24.7 ± 6.2 
 
Systolic blood pressure, 
mmHg 
143 ± 21 145 ± 16 145 ± 20 
 
Diastolic blood pressure, 
mmHg 
81 ± 7 83 ± 11 82 ± 4 
 
Total cholesterol, mg/dL 207 ± 23 215 ± 26 219 ± 24 ** 
HDL-cholesterol, mg/dL 53 ± 12 51 ± 20 54 ± 16 
 
LDL-cholesterol, mg/dL 124 ± 24 136 ± 22 134 ± 18 *, ** 
Triglycerides, mg/dL 138 ± 31 138 ± 40 155 ± 25 **, *** 
Categorical variables, n (%) 
CHD risk factors 
Male gender 52.4 42.6 57.5 
 
Obesity (BMI ≥ 30) 8.5 34.0 30.0 *,** 
Dyslipidemia 44.9 40.4 52.5 
 
Hypertension 48.0 70.2 42.5 * 
Current smoking 29.3 34.0 35.0 
 
Family history 32.7 36.2 47.5 
 
Diabetes mellitus 
(follow-up) 
2.4 4.3 5.0 
 
High-risk for fatal CHD 
(score ≥ 5%) 
11.3 15.2 18.2 
 
Medications 
β-Blockers 34.4 34.0 37.5 
 
Calcium channel 
blockers 
21.8 31.9 25.0 
 
ACE-inhibitors 30.6 36.2 40.0 
 
Statins 25.2 21.3 35.0 
 
Antiplatelet drugs 38.1 42.6 35.0 
 
*No depression versus mild depression; **No depression versus moderate/severe depression; ***Mild depression 
versus moderate/severe depression. For continuous variables: all comparisons tested using one-way ANOVA with a 
Sidak correction. For categorical variables, the p-values were computed using the chi-squared test. IQR = Interquartile 
range. 
  
Table 2. Selected inflammatory markers and indices of heart rate variability by depression 
status. 
 
No depression 
(n = 294) 
Mild 
depression 
(n = 47) 
Moderate/severe 
depression (n = 40) p < 0.05 
Mean ± SD Mean ± SD Mean ± SD 
Inflammation markers 
    
C-Reactive protein, mg/dL 
(baseline) 
0.76 ± 0.27 1.01 ± 0.33 1.61 ± 0.83 
*, **, 
*** 
C-Reactive protein, mg/dL 
(end of follow-up) 
0.77 ± 0.27 0.91 ± 0.39 1.67 ± 0.83 **, *** 
% of change (end of follow-
up – baseline) 
8.9 ± 73.9 −13.4 ± 14.7 4.5 ± 14.5 
 
Interleukin-6, pg/mL 
(baseline) 
1.7 ± 0.6 1.9 ± 0.7 2.1 ± 0.4 *, ** 
Interleukin-6, pg/mL (end of 
follow-up) 
1.7 ± 0.7 1.8 ± 0.7 2.2 ± 0.5 **, *** 
% of change (end of follow-
up – baseline) 
−1.4 ± 14.4 −6.3 ± 8.3 2.7 ± 8.0 ** 
Time-domain measurements 
of heart rate variability 
(baseline) 
    
Heart rate, bpm/min 
(baseline) 
66 ± 10 68 ± 10 67 ± 13 
 
Heart rate, bpm/min (end of 
follow-up) 
66 ± 8 64 ± 8 62 ± 6 *** 
% of change (end of follow-
up – baseline) 
3.1 ± 21.0 −4.9 ± 15.5 −4.6 ± 22.8 * 
SDNN, ms (baseline) 115 ± 18 107 ± 15 101 ± 10 *, ** 
SDNN, ms (end of follow-up) 110 ± 23 90 ± 12 90 ± 8 *, *** 
% of change (end of follow-
up – baseline) 
−3.6 ± 15.7 −14.7 ± 7.8 −11.0 ± 10.5 *, ** 
SDANN, ms (baseline) 108 ± 23 92 ± 12 92 ± 8 *, ** 
SDANN, ms (end of follow-
up) 
116 ± 19 105 ± 15 99 ± 10 *, *** 
% of change (end of follow-
up – baseline) 
10.2 ± 19.8 13.3 ± 10.0 9.4 ± 15.5 
 
RMSSD, ms (baseline) 19.3 ± 5.9 18.0 ± 6.0 16.6 ± 4.8 ** 
RMSSD, ms (end of follow-
up) 
19.7 ± 10.1 16.0 ± 6.0 14.6 ± 4.8 *, ** 
% of change (end of follow-
up – baseline) 
1.1 ± 35.7 −12.6 ± 5.0 −13.3 ± 4.7 *, ** 
pNN50, % (baseline) 6.5 ± 3.3 5.8 ± 3.3 5.6 ± 2.7 
 
pNN50, % (end of follow-up) 6.4 ± 3.4 6.5 ± 4.3 3.9 ± 2.3 **, *** 
% of change (end of follow-
up – baseline) 
−1.7 ± 22.6 20.3 ± 64.2 −26.2 ± 39.5 
*, **, 
*** 
*No depression versus mild depression; **No depression versus moderate/severe depression; ***Mild depression 
versus moderate/severe depression (all comparisons tested using one-way ANOVA with a Sidak correction). 
SDNN = standard deviation of the mean value of time between normal complexes. SDANN = standard deviation of the 
average of NN intervals for each 5 min period. RMSSD = square root of mean square successive difference of RR 
intervals. pNN50 = mean percentage of successive NN interval differences >50 ms. 
  
Table 3 Selected indices of subclinical atherosclerosis by depression status. 
 
No depression 
(n = 294) 
Mild depression 
(n = 47) 
Moderate/severe 
depression (n = 40) p < 0.05 
Mean ± SD Mean ± SD Mean ± SD 
Indices of subclinical atherosclerosis, mm 
Intima–media thickness – 
left (baseline) 
0.76 ± 0.14 0.85 ± 0.20 1.08 ± 0.29 
*, **, 
*** 
Intima–media thickness – 
left (end of follow-up) 
0.92 ± 0.20 1.16 ± 0.29 1.69 ± 0.59 
*, **, 
*** 
Intima–media thickness – 
right (baseline) 
0.76 ± 0.13 0.83 ± 0.19 1.07 ± 0.30 
*, **, 
*** 
Intima–media thickness – 
right (end of follow-up) 
0.93 ± 0.20 1.15 ± 0.31 1.68 ± 0.60 
*, **, 
*** 
Intima–media thickness – 
mean (baseline) 
0.76 ± 0.13 0.84 ± 0.19 1.08 ± 0.29 
*, **, 
*** 
Intima–media thickness – 
mean (end of follow-up) 
0.92 ± 0.20 1.12 ± 0.31 1.69 ± 0.60 
*, **, 
*** 
Δ (end of follow-up – baseline) 
Mean intima–media 
thickness – mean change 
0.16 ± 0.14 0.31 ± 0.28 0.61 ± 0.54 
*, **, 
*** 
Mean intima–media 
thickness – % of change 
21.8 ± 20.6 39.8 ± 39.4 59.9 ± 56.6 
*, **, 
*** 
*No depression versus mild depression; **No depression versus moderate/severe depression; ***Mild depression 
versus moderate/severe depression (all comparisons tested using one-way ANOVA with a Sidak correction). 
  
Table 4 Relationship between depression symptoms (reference category = no depression) and 
intima media thickening (IMT) increase (in mm) during follow-up. 
 
Coefficient 
Standardized 
coefficient 
Robust standard 
errors 
p 
Adjusted for age and gender 
Mild depression (9 < BDI < 19) 0.150 0.180 0.042 <0.001 
Moderate and severe depression 
(BDI ≥ 19) 
0.452 0.506 0.085 <0.001 
Adjusted for demographic and CHD risk factors
a
 
Mild depression (9 < BDI < 19) 0.149 0.179 0.042 <0.001 
Moderate and severe depression 
(BDI ≥ 19) 
0.446 0.499 0.084 <0.001 
Also adjusted for drug use
b
 
Mild depression (9 < BDI < 19) 0.156 0.187 0.043 <0.001 
Moderate and severe depression 
(BDI ≥ 19) 
0.445 0.498 0.083 <0.001 
Also adjusted for autonomic indices
c
 
Mild depression (9 < BDI < 19) 0.156 0.187 0.043 <0.001 
Moderate and severe depression 
(BDI ≥ 19) 
0.433 0.485 0.082 <0.001 
Also adjusted for C-reactive protein and IL-6 
Mild depression (9 < BDI < 19) 0.073 0.088 0.040 0.068 
Moderate and severe depression 
(BDI ≥ 19) 
0.259 0.290 0.069 <0.001 
Other significant predictors of IMT increase (fully adjusted model) 
Logarithm of C-reactive protein 
(mg/dL) 
0.207 0.385 0.035 <0.001 
Aspirin use −0.058 −0.104 0.022 0.010 
Familial history of CHD 0.062 0.107 0.026 0.017 
SDNN −0.003 −0.203 0.001 <0.001 
Variables not reported in the table were not significant in the regression models. 
aAge, gender, body mass index, current smoking, familiarity for CHD, systolic blood pressure, total cholesterol, HDL-
cholesterol and triglycerides, and global CHD risk at ten years according to the SCORE system. 
bBeta-blockers (yes versus no), ACE-antagonists, calcium-antagonists, diuretics, sartans, statins, SSRIs, and aspirin. 
cHeart rate (1-bpm increase), SDNN (standard deviation of the mean value of time between normal complexes), 
SDANN (standard deviation of the average of NN intervals for each 5 min period), RMSSD (square root of mean 
square successive difference of RR intervals), and pNN50 (mean percentage of successive NN interval differences 
>50 ms). 
  
Table 5 Relationship between depression symptoms and Intima media thickening. Subjects 
with carotid wall thickening (>0.9 mm) at baseline were excluded. 
 
OR 
IMT > 0.9 mm 
p 
(95% CI) 
Unadjusted analysis 
Depression group, ordinal (no depression as the ref. 
category) 
3.05 (1.76–5.31) <0.001 
Adjusted analysis
a
 
Depression group, ordinal (no depression as the ref. 
category) 
1.96 (1.05–3.63) 0.032 
OR = odds ratio; CI = confidence interval. Logistic regression model with 314 observations. Hosmer–Lemeshow 
goodness of fit p-value = 0.52; Area under the ROC curve = 0.76. 
aIncluding age, gender, body mass index, current smoking, familiarity for CHD, systolic blood pressure, aspirin use, 
Interleukin-6 level, SDNN (standard deviation of the mean value of time between normal complexes), SDANN 
(standard deviation of the average of NN intervals for each 5 min period), RMSSD (square root of mean square 
successive difference of RR intervals), and pNN50 (mean percentage of successive NN interval differences >50 ms). 
 
 
